Catalent Expert to Present Advanced Technology Solutions for Today's Biologics Challenges
Somerset, NJ – September 27, 2011 – Kent Payne, Ph.D., Vice President and General Manager, Development and Clinical Services, at Catalent Pharma Solutions is to present at the One Nucleus Life Science Leadership – Healthcare Technologies event in Cambridge, UK. Dr. Payne’s presentation, “Advanced Technology and Service Solutions for Today’s Biologics Challenges” will take place at Clare College on Thursday, September 29, 2011 from 11:15 am to 11:45 am.
Dr. Payne will discuss how candidate selection programs can be used to balance risk and innovation against potential, and cost of further development. He will contend that the selection of development partners with advantaged technologies and broad product development capabilities may better ensure internal resources are available for development from gene to clinic. Topics will include:
- the ability to move from cDNA to gram quantities of protein from a high expressing cell pool in a commercial production media in 12 weeks with Catalent’s GPEx® system provides discovery scientists a powerful tool to screen multiple constructs in a short period of time and increases the potential of selecting an optimal target
- why selecting technologies that provide higher expression levels at cell pool or clonal selection stage increases the probability of higher efficiencies being achieved later through upstream/downstream development activities and ultimately mean the difference between reaching the next milestone and being advantaged all the way to market
- why it is important for discovery teams to have access to partners with a broad range of capabilities beyond the mainstay sterile delivery mechanisms; for example, to rapidly contrast proteins intended for delivery via the inhaled route of administration
For more information on this event, please visit: www.onenucleus.com
Dr. Kent Payne is currently the Vice President and General Manager within the Development and Clinical Services business at Catalent. Prior to joining Catalent, Dr. Payne was vital in developing the Pharmaceutical Development outsourcing business within Cardinal Health, a Fortune 19 company. Previously he worked for the Novartis Institute for Biomedical Research and, prior to that, held positions at G.D. Searle where he was also an Associate Fellow. He also serves as Non-Executive Board Chairman for PDS Biotechnology Corporation. As a business leader, Dr. Payne has been successful leading start-up, growth, and turn-around situations and is an advocate of Operational Excellence and Lean/Six Sigma principles.
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,200 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.